Impact Factor
3.76
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.02
826 total citations
h5-index
37
h5 depth signal
Cited share
83.5%
177 of 212
Total citations
826
Citation footprint
Metric signal
3.83
External metric anchor
Self-citation
1.2%
10 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
365
Italy
237
China
155
United Kingdom
100
Spain
70
Citing Fields of Research
Cardiology
111
Pharmacology & Toxicology
107
Diabetes
107
Oncology
97
Allergies
71
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,940
Articles tracked across the journal lifetime
Indexed publication set
212
177 cited publications
Last 12 months
111
9.3 publications/month
Open access share
19.8%
22 OA publications in the last year
Leading citing country
United States
365 citing publications
Leading citing field
Cardiology
111 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Jan. 2011-
v4n1, Jan. 2011-
Research Focus & Classification
Indexed Subjects
Cardiology
Diabetes
Oncology
Hematology
Musculoskeletal Disorders
Allergies
Patient Care
Broad Categories
Pharmacology
Diabetes
Allergies
Urology
Medical Ethics
Hematology
HIV
Patient Care
MeSH Descriptors
Pharmacology, Clinical
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/17512433.2026.2750908
Open DOI
Present and future of ulta-low- and low-dose triple combination therapy in hypertension: a clinical practice perspective
It is increasingly recognized that initial monotherapy is insufficiently effective for sustained blood pressure (BP) control in the large majority of people with hypertension. Ultra-low- and low-dose combination therapy has emerged as a ...
02
DOI 10.1080/17512433.2026.2749579
Open DOI
Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study
03
04
DOI 10.1080/17512433.2026.2744253
Open DOI
Emerging pharmacological therapies for bronchiectasis
05
DOI 10.1080/17512433.2026.2742316
Open DOI
Limitations of current neuroprotective therapies in dementia with Lewy bodies
1. Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline sufficient to interfere with daily activities or social/occupational function (i.e....
06
DOI 10.1080/17512433.2026.2744573
Open DOI
Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group
1. Urothelial carcinoma (UC) represents one of the most frequent malignancies of the urinary tract and remains associated with a substantial global burden. According to recent epidemiological estim...
07
DOI 10.1080/17512433.2026.2742318
Open DOI
Off-label drug use in children: prevalence, risks, and regulation
1. Pediatric development is a dynamic process characterized by ongoing physiological and cognitive changes from birth through adolescence. Children are therefore not simply “small adults”: their or...
08
DOI 10.1080/17512433.2026.2739561
Open DOI
Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning
1. Non-cystic fibrosis bronchiectasis (NCFB) is increasingly recognized as a major chronic airway disease with substantial clinical, microbiological and healthcare consequences, rather than as a ra...
09
DOI 10.1080/17512433.2026.2739122
Open DOI
Authors’ reply: evidential standards, levels of inference, and shared objectives
We thank the correspondent for their engagement with our editorial [1,2]. Their central concern, that evidence generation has repeatedly failed to translate into timely protective action, is one we...
10
DOI 10.1080/17512433.2026.2738821
Open DOI
Drug safety and pregnancy: more evidence or changing mindset?
Despite being an advocate of evidence-based medicine, I was struck by the publication of an editorial calling for improved evidence-based antiseizure medication prescribing during pregnancy [1].Fir...
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Also issued online.